Smart Investing: $TLRY Rakes in +5.02% Profits via Automated Trading.
Artificial intelligence-powered trading robots have been making waves, demonstrating their capabilities in the volatile world of finance. At "Trend Trader, Popular Stocks: Price Action Trading Strategy (TA&FA)," these AI-driven bots successfully generated a remarkable +5.02% gain while trading TLRY over the previous week. In this article, we delve into the technical analysis of TLRY's recent performance, focusing on key indicators, earnings results, market capitalization, and notable price and volume movements within the Pharmaceuticals: Other Industry.
Technical Indicator Insights: TLRY's RSI Oscillator
One notable technical signal for TLRY is the movement of its 10-day Relative Strength Index (RSI) Oscillator. On December 29, 2023, the RSI moved out of the overbought zone, suggesting a potential shift from an upward to a downward trend. According to Tickeron's A.I.dvisor, in 15 out of 16 instances where the RSI exited the overbought zone, the stock moved lower in the subsequent days. This statistical pattern places the odds of a downward move at a substantial 90%. Traders are advised to consider selling the stock or exploring put options in response to this signal.
Earnings Report Overview: January 09, 2024
TLRY's latest earnings report, dated January 09, 2024, revealed earnings per share of -7 cents, falling short of the estimated -5 cents. The company, with 12.73 million shares outstanding, currently holds a market capitalization of 1.29 billion. Analyzing the earnings miss and its impact on the stock's valuation provides valuable insights for investors considering their positions in TLRY.
Market Capitalization Comparison in Pharmaceuticals: Other Industry
Comparing TLRY's market capitalization with industry peers is crucial for understanding its relative standing. In the Pharmaceuticals: Other Industry, the average market capitalization is 2.79 billion, with a range spanning from 246 million (PEMTF) to a staggering 82.08 billion (ZTS). TLRY's position within this spectrum influences its attractiveness to investors and potential for future growth.
Price Movement Metrics: Highs, Lows, and Industry Averages
Analyzing TLRY's price movements alongside industry benchmarks provides context for evaluating its performance. The average weekly, monthly, and quarterly price growth across all stocks in the Pharmaceuticals: Other Industry stands at 0%, 34%, and 21%, respectively. TLRY's individual price trajectory becomes more apparent when compared to its industry counterparts, offering insights into its relative strength and weaknesses.
Notable high and low price movements within the industry further highlight TLRY's performance. With UPC experiencing the highest price growth at 66%, and CNGGF witnessing a significant fall at -52%, understanding these extremes aids in contextualizing TLRY's own price dynamics.
Volume Trends in Pharmaceuticals: Other Industry
Examining TLRY's trading volume alongside industry trends is essential for assessing investor sentiment. The average weekly, monthly, and quarterly volume growth across all stocks in the Pharmaceuticals: Other Industry is -3%, 34%, and -17%, respectively. TLRY's volume trends, compared to industry averages, provide valuable insights into the level of interest and activity surrounding the stock.
In summary, the technical analysis of TLRY's recent performance, encompassing indicators, earnings results, market capitalization, price movements, and volume trends, offers investors a comprehensive understanding of the stock's current position and potential future trajectory.
Momentum Indicator for TLRY turns negative, indicating new downward trend
TLRY saw its Momentum Indicator move below the 0 level on March 03, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned negative. In of the 79 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for TLRY turned negative on March 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for TLRY entered a downward trend on March 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TLRY's RSI Indicator exited the oversold zone, of 48 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in of 204 cases, the price rose further within the following month. The odds of a continued upward trend are .
TLRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.508) is normal, around the industry mean (25.901). P/E Ratio (0.000) is within average values for comparable stocks, (64.566). TLRY's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.973). TLRY has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (0.833) is also within normal values, averaging (113.085).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. TLRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company, whose subsidiaries engages in research, cultivation, processing and distribution of medical cannabis
Industry PharmaceuticalsGeneric
Advertisement